Briggs Morrison, Syndax Pharmaceuticals CEO (Syndax)
Syndax looks to rebound from stinging late-stage failure, uncorking early data for next cancer drug up
A year ago, Syndax Pharmaceuticals suffered a major Phase III flop that forced it to forgo an FDA filing for its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
